Increased serum levels of quinolinic acid indicate enhanced severity of hepatic dysfunction in patients with liver cirrhosis

Alpha fetoprotein (AFP) has been used as a serologic indicator of hepatocellular carcinoma (HCC). We aimed to identify an HCC-specific serum biomarker for diagnosis using a multiplexed proteomic technique in HCC patients with normal AFP levels. A total of 152 patients were included from Guro Hospital, Korea University. Among 267 identified proteins, 28 and 86 proteins showed at least a two-fold elevation or reduction in expression, respectively. Multiple reaction monitoring (MRM) analysis of 41 proteins revealed 10 proteins were differentially expressed in patients with liver cirrhosis and HCC patients with normal AFP. A combination of tripartite motif22 (Trim22), seprase, and bone morphogenetic protein1 had an area under receiver operating characteristic of 0.957 for HCC diagnosis. Real-time PCR and western blot analysis of the paired tumor/non-tumor liver tissue in HCC revealed a reduced expression of Trim22 in the tumor tissue. Also, serum levels of Trim22 were significantly reduced in HCC patients with normal AFP compared to those with liver cirrhosis (p = 0.032). Inhibition of Trim22 increased cellular proliferation in human hepatoma cell lines, whereas overexpression of Trim22 decreased cellular proliferation in hepatoma cell lines. In conclusion, the combination of three serum markers improved the chance of diagnosing HCC. MRM-based quantification of the serum protein in patients with normal AFP provides the potential for early diagnosis of HCC.

Download Full-text

VITAMIN D SERUM LEVELS IN PATIENTS WITH LIVER CIRRHOSIS IN SOUTHERN IRAN

Acta healthmedica ◽

10.19082/ah223 ◽

2017 ◽

Vol 2 (4) ◽

pp. 223-228

Author(s):

Seyed Hamid Moosavy ◽

Arash Rahimi

Keyword(s):

Vitamin D ◽

Liver Cirrhosis ◽

Serum Levels ◽

Southern Iran

Download Full-text

Relationship between NT-proBNP and Cardio-Renal Dysfunction in Patients with Advanced Liver Cirrhosis

Journal of Gastrointestinal and Liver Diseases ◽

10.15403/jgld-1279 ◽

2014 ◽

Vol 23 (1) ◽

pp. 51-56 ◽

Cited By ~ 2

Author(s):

Adriana Cavasi ◽

Eduard Cavasi ◽

Mircea Grigorescu ◽

Adela Sitar-Taut

Keyword(s):

Liver Cirrhosis ◽

Liver Disease ◽

Renal Dysfunction ◽

Cardiac Dysfunction ◽

Serum Levels ◽

Qtc Interval ◽

Advanced Liver Cirrhosis ◽

Group 3 ◽

Group 2 ◽

Group 1

Background & Aims: ProBNP is a sensitive marker of cardiac dysfunction. We assessed the concentration of circulating NT-proBNP in patients with liver cirrhosis in various stages of the disease and its correlation with markers of cardiac and renal dysfunction and with markers of liver disease severity.Patients and methods: A number of 88 patients with liver cirrhosis were included in the study, divided into 3 groups: group 1 - 18 control patients without ascites; group 2 - 35 non-azotemic patients with ascites; group 3 - 35 patients with hepatorenal syndrome. The cardiac dysfunction was assessed by measuring the NT-proBNP serum levels and the QTc interval. The markers of renal dysfunction were the estimated glomerular filtration rates - formulas involving creatinine and serum cystatin C. The Child-Pugh score was used to assess the liver disease severity.Results: The median NT-proBNP serum levels significantly increased in patients with advanced liver cirrhosis (group 3: 960 fmol/ml and group 2: 660 fmol/ml) as compared to group 1 (435 fmol/ml) (p<0.05). A significant direct correlation was found between the NT-proBNP concentration and the QTc interval (r=0.540, p<0.001). The NT-proBNP levels also correlated with the Child-Pugh score (r=0.501, p<0.01), proving the link between the cardiac dysfunction and the liver disease severity. The cardio-renal interrelation is supported by the relationship between the NT-proBNP concentration and the estimated clearances.Conclusion: The high NT-proBNP levels in patients with advanced cirrhosis indicate the presence of cardiac dysfunction, which has a role in the pathogenesis of the hepatorenal syndrome.Abbreviations: DP: diastolic pressure; GFR: glomerular filtration rate; HRS: hepatorenal syndrome; MAP:mean arterial pressure; NT-proBNP: N-terminal fragment of the prohormone B-type natriuretic peptide; proBNP: prohormone brain natriuretic peptide; SBP: spontaneous bacterial peritonitis; SP: systolic pressure; TIPS: tranjugular intrahepatic portosystemic shunt.

Download Full-text

Splenomegaly and thrombocytopenia in patients with liver cirrhosis

Vojnosanitetski pregled ◽

10.2298/vsp1002166d ◽

2010 ◽

Vol 67 (2) ◽

pp. 166-169 ◽

Cited By ~ 9

Author(s):

Jelena Djordjevic ◽

Petar Svorcan ◽

Dusica Vrinic ◽

Branka Dapcevic

Keyword(s):

Risk Factors ◽

Liver Cirrhosis ◽

Platelet Count ◽

Portal Hypertension ◽

Hepatic Dysfunction ◽

Spleen Size ◽

Hepatitis Viruses ◽

Decompensated Liver Cirrhosis ◽

Splenic Sequestration ◽

Frequent Finding

Backgroud/Aim. Splenomegaly is a frequent finding in patients with liver cirrhosis and portal hypertension and may cause hypersplenism. The occurrence of thrombocytopenia in those patients can be considered as an event with multiple etiologies. Two mechanisms may act alone or synergistically with splenic sequestration. One is central which involves either myelosuppression because of hepatitis viruses or the toxic effects of alcohol abuse on the bone marrow. The second one involves the presence of antibodies against platelets. It also depends upon the stage and etiology of liver disease. The aim of the study was to investigate a correlation between the platelet count and spleen size and the risk factors for thrombocytopenia in patients with liver cirrhosis. Methods. We studied 40 patients with decompensated liver cirrhosis who were hospitalized in the Department of Gastroenterohepatology. The liver function was graded according to Child Pugh score. Spleen size was defined ultrasonografically on the basis of craniocaudal length. Suspicion of portal hypertension was present when longitudinal spleen length was more than 11 cm. Thrombocytopenia was determined by platelet count under 150 000/mL. Results. We did not find any significant correlation between hepatic dysfunction and spleen size (p = 0.9), and between hepatic dysfunction and thrombocytopenia (p = 0.17). Our study did not find any significant correlation between spleen size and peripheral platelet count (p = 0.5), but we found a significant correlation between thrombocytopenia and etiology of cirrhosis - decreased platelet count was more common among patients with cirrhosis of alcoholic etiology than in other etiologies of cirrhosis (p = 0.001). Conclusion. According to our study, liver cirrhosis, portal hypertension and thrombocytopenia could be present even in the absence of enlarged spleen suggesting the involvement of other mechanisms of decreasing platelet account.

Download Full-text

Genetic polymorphisms of interleukin-6 influence the development of hepatitis B virus-related liver cirrhosis

10.21203/rs.2.522/v1 ◽

2019 ◽

Author(s):

Caixia Xia ◽

Wei Zhu ◽

Chunhong Huang ◽

Guohua Lou ◽

Bingjue Ye ◽

...

Keyword(s):

Liver Cirrhosis ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Interleukin 6 ◽

Serum Levels ◽

Healthy Controls ◽

Nucleotide Polymorphisms ◽

Cross Sectional ◽

B Virus ◽

Infected Liver

Abstract Background Interleukin-6 (IL-6) plays an important role in chronic inflammation. Thus, we aimed to investigate the effects of IL-6 polymorphisms in predicting the progression of hepatitis B virus (HBV) -related liver cirrhosis. Methods A cross-sectional study was conducted to analysis IL-6 polymorphisms and serum levels of IL-6 in HBV-infected patients of different clinical phases and in healthy controls. IL-6 polymorphisms were detected by Taqman PCR method and plasma IL-6 levels were assessed by ELISA. Results Our analysis included 182 chronic hepatitis B (CHB) patients, 190 HBV-infected liver cirrhosis cases, 125 inactive HBsAg carriers, and 246 healthy controls. Seven SNPs in IL-6 including rs10499563, rs17147230, rs1800796, rs2069837, rs1524107, rs2066992, rs2069852 were analyzed. In haplotype analysis between HBV-infected liver cirrhosis cases with CHB patients, inactive HBV-carriers or healthy controls, haplotype CT in block 1 and haplotype GGCGG in block 2 were associated with liver cirrhosis (P<0.05). What’s more, the genotype or allele frequencies were significantly different in IL-6 rs10499563 and rs2069837 when HBV-infected liver cirrhosis patients compared with CHB patients, inactive HBV-carriers or healthy controls. A further study found that compared with the controls or CHB patients, plasma IL-6 was elevated in HBV-infected liver cirrhosis patients (P<0.05). Conclusion In conclusion, the polymorphisms of the IL-6 rs10499563 and rs2069837 are associated with the susceptibility of liver cirrhosis may through their effects on IL-6 expressions and these two single nucleotide polymorphisms can be used as potential predicting markers for prognosis of HBV-infected liver cirrhosis.

Download Full-text

Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma

The American Journal of Gastroenterology ◽

10.1111/j.1572-0241.2007.01377.x ◽

2007 ◽

Vol 102 (11) ◽

pp. 2471-2481 ◽

Cited By ~ 33

Author(s):

Arne Scholz ◽

Vanessa Annina Rehm ◽

Svenja Rieke ◽

Katja Derkow ◽

Petra Schulz ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Cirrhosis ◽

Serum Levels ◽

Angiopoietin 2

Download Full-text

Hepatic Encephalopathy: From the Pathogenesis to the New Treatments

ISRN Hepatology ◽

10.1155/2014/236268 ◽

2014 ◽

Vol 2014 ◽

pp. 1-16 ◽

Cited By ~ 11

Author(s):

Juan Cordoba

Keyword(s):

Clinical Trials ◽

Liver Cirrhosis ◽

Hepatic Encephalopathy ◽

Prospective Studies ◽

Hepatic Dysfunction ◽

Short Term ◽

Multiple Factors ◽

Short Term Mortality ◽

Cirrhotic Patients ◽

New Treatments

Hepatic encephalopathy is a frequent and serious complication of liver cirrhosis; the pathophysiology of this complication is not fully understood although great efforts have been made during the last years. There are few prospective studies on the epidemiology of this complication; however, it is known that it confers with high short-term mortality. Hepatic encephalopathy has been classified into different groups depending on the degree of hepatic dysfunction, the presence of portal-systemic shunts, and the number of episodes. Due to the large clinical spectra of overt EH and the complexity of cirrhotic patients, it is very difficult to perform quality clinical trials for assessing the efficacy of the treatments proposed. The physiopathology, clinical manifestation, and the treatment of HE is a challenge because of the multiple factors that converge and coexist in an episode of overt HE.

Download Full-text